PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
5.21
P/E 1.25-1.5x Medical - Pharmaceuticals median of 3.57. Howard Marks would be cautious of market optimism. Verify all growth assumptions.
0.51
P/S less than half the Medical - Pharmaceuticals median of 5.55. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
1.03
P/B 50-90% of Medical - Pharmaceuticals median of 1.22. Mohnish Pabrai would examine if this discount presents opportunity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.03
Fair value ratio 50-90% of Medical - Pharmaceuticals median of 1.22. Mohnish Pabrai would examine if this gap presents opportunity.
4.80%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 0.71%. Joel Greenblatt would investigate if high yield reflects hidden value.
No Data
No Data available this quarter, please select a different quarter.